Skip to main content
. 2017 Oct 19;2017:6835782. doi: 10.1155/2017/6835782

Table 1.

Patient and treatment characteristics.

Eyes (patients), n 164 (134)
Mean age (range), years 75.9 (56–92)
Women, n (%) 75 (56.0)
Angiographic classification, n (%)
 Occult with no classic 95 (57.9)
 Predominantly classic 37 (22.6)
 Minimally classic 11 (6.7)
 Polypoidal choroidal vasculopathy 14 (8.5)
 Retinal angiomatous proliferation 7 (4.3)
Eyes refractory to bevacizumab, n (%) 101 (61.6)
Eyes on treatment with ranibizumab, n (%) 63 (38.4)
Mean time on therapy ± SD, months
 Prior to switch 28.5 ± 19.1
 Aflibercept 29.9 ± 9.0